10-Q: Oramed Q2 2025: JV Delayed, Shifts to Investments

Oramed Pharmaceuticals reports mixed Q2 2025 results, with a significant increase in net income driven by investment revaluations, despite a delayed oral insulin joint venture and increased R&D spending.

Summary

• Net income for the three months ended June 30, 2025, increased to $13.26 million, up from $9.20 million in Q2 2024, primarily due to revaluation of investments.
• Net income for the six months ended June 30, 2025, decreased to $5.62 million from $10.74 million in the prior year period.
• The joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) for oral insulin development is on hold due to U.S.-China trade tensions, leading to a pause in the planned U.S. Phase 3 clinical trial.
• Cash and cash equivalents significantly decreased to $15.80 million as of June 30, 2025, from $54.42 million at December 31, 2024, largely due to new investments.
• The company made substantial new investments, including $36.9 million in Alpha Tau Medical Ltd. for a 16.65% stake and significant real estate loans totaling $26.92 million.
• Research and development expenses increased by 24% to $3.24 million for the six months ended June 30, 2025, driven by preparations for a new Phase 3 clinical trial (ORA-D-013-3).
• Oramed entered an option agreement with Scilex Holding Company for the repurchase of 6.5 million Subsequent Penny Warrants for $27 million, with an initial $750,000 fee received.
• The company's stock buyback program was extended for one year, with $17.16 million remaining authorization.

Sentiment

Score: 4

Explanation: While Q2 net income showed a positive revaluation of investments, the overall six-month financial performance indicates a significant decline in net income and cash reserves. The core pharmaceutical business faces a major setback with the indefinite delay of the oral insulin joint venture and associated Phase 3 trial due to external geopolitical factors. The company's strategy of diversifying into real estate and other biotech investments, while potentially offering long-term value, also introduces new risks and shifts focus away from its primary R&D mission. The Scilex warrant repurchase option provides a potential cash inflow but is subject to Scilex's ability to pay. The overall picture is one of significant operational delays and a strategic pivot that carries both opportunity and increased risk.

Positives

• Net income for the three months ended June 30, 2025, increased to $13.26 million from $9.20 million in the same period last year.
• Basic income per share for Q2 2025 increased to $0.32 from $0.22 in Q2 2024.
• Diluted income per share for Q2 2025 increased to $0.31 from $0.22 in Q2 2024.
• Accumulated deficit decreased from $176.62 million at December 31, 2024, to $170.97 million at June 30, 2025.
• Significant unrealized gain of $7.14 million on the investment in Alpha Tau Medical Ltd. for the six months ended June 30, 2025.
• Successful repayment of $3.63 million ($3.13 million principal, $0.50 million interest) from Scilex for the Tranche B Note in July 2025.
• Secured an option agreement with Scilex to repurchase 6.5 million Subsequent Penny Warrants for $27 million, with an initial non-refundable fee of $750,000 already received.
• The company's stock buyback program was extended for another year, demonstrating confidence in its valuation and commitment to shareholder returns.
• The company has diversified its investment portfolio into real estate and other biotech companies (Alpha Tau, BioXcel, Pelthos), aiming for long-term value appreciation and income streams.
• Resolved all obligations to the Israel Innovation Authority (IIA) by remitting $2.05 million, clearing the path for technology transfer to OraTech.

Negatives

• Net income for the six months ended June 30, 2025, decreased to $5.62 million from $10.74 million in the same period last year.
• Basic income per share for H1 2025 decreased to $0.14 from $0.26 in H1 2024.
• Diluted income per share for H1 2025 decreased to $0.13 from $0.26 in H1 2024.
• Cash and cash equivalents decreased significantly by $38.62 million, from $54.42 million at December 31, 2024, to $15.80 million at June 30, 2025.
• Net cash used in operating activities was $7.05 million for H1 2025, a shift from $0.60 million provided in H1 2024.
• Net cash used in investing activities increased substantially to $31.24 million for H1 2025, compared to $124.65 million provided in H1 2024, indicating significant capital deployment.
• The joint venture with HTIT is on hold due to U.S.-China trade tensions, delaying the development and commercialization of oral insulin and pausing the planned U.S. Phase 3 clinical trial.
• Financial income, net, decreased to $12.81 million for H1 2025 from $19.32 million in H1 2024, primarily due to revaluation of Scilex and RoyaltyVest investments and lower interest income.
• The fair value of the Tranche A Note and Tranche B Note from Scilex remains less than their aggregate unpaid principal balances by $9.34 million and $7.57 million, respectively, as of June 30, 2025.
• The company sold its remaining 164,286 shares of Scilex common stock in July-August 2025, indicating a full exit from direct equity holdings in Scilex.

Risks

• The ability to realize the full value of the Option Agreement with Scilex or complete the repurchase of Subsequent Penny Warrants is uncertain, as Scilex may not make required payments or complete the repurchase.
• If the Option Agreement terminates, the ability to monetize or exercise the 6.5 million Subsequent Penny Warrants is limited by Nasdaq Listing Rule 5635(d), which requires shareholder approval for issuing securities exceeding 20% of outstanding shares at below-market prices, potentially preventing full economic benefit.
• Various real estate and other investments, including Alpha Tau Medical Ltd., involve significant risks and may not provide expected long-term value appreciation or income streams.
• If Alpha Tau fails to achieve positive clinical results or obtain regulatory approvals, the value of the investment could decline materially, adversely affecting financial results.
• Conditions in the real estate market might change, affecting the value of real estate investments.
• Ongoing U.S.-China trade tensions have delayed HTIT's ability to obtain necessary regulatory approvals for its capital contribution and closing obligations under the JV Agreement, raising concerns about HTIT's near-term supply and manufacturing support.
• The company's plan to initiate a Phase 3 clinical trial in the U.S. for oral insulin is paused pending clarity on the HTIT JV, potentially delaying product development.
• The company is exposed to potential market, liquidity, and execution risks from its loan agreement in real estate projects (Profit Sharing Loan Agreement).
• The company's operations in Israel expose it to political, economic, and military risks, although no immediate risk to business operations related to the Israel-Hamas conflict was identified as of August 13, 2025.

Future Outlook

The company plans to evaluate potential strategic opportunities, including modified structures for the HTIT joint venture or alternative partners to advance its oral insulin program independently. Research and development expenses are expected to increase with the preparation and initiation of the revised Phase 3 clinical trial (ORA-D-013-3), either directly or through OraTech. The company believes its current cash resources and commitments will sustain planned activities for at least the next 12 months. Real estate and other investments are intended to enhance financial flexibility and maximize shareholder value, with expectations of long-term value appreciation and potential income streams. The company is assessing the impact of the recently signed One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements.

Management Comments

• "We are evaluating whether a modified structure with HTIT is feasible under current conditions and concurrently exploring alternative partners and pathways to advance the program independently."
• "As we continue to evaluate our business strategy, including potential structural changes, these investments are intended to enhance financial flexibility and maximize shareholder value."
• "As investors, we believe Alpha Tau represents a compelling opportunity—combining innovative science, a scalable platform, and growing regulatory momentum."
• "Based on our current cash resources and commitments, we believe we will be able to maintain our current planned activities and the corresponding level of expenditures for at least the next 12 months."
• "We expect that in the upcoming years our research and development expenses will continue to be our major operating expense, either directly or under the JV Agreement; however, if this clinical trial is conducted through OraTech, these costs will be borne by OraTech and not by us."

Industry Context

Oramed Pharmaceuticals operates in the highly competitive and capital-intensive pharmaceutical industry, specifically focusing on oral drug delivery technology. The delay in its oral insulin joint venture due to U.S.-China trade tensions highlights geopolitical risks impacting global biotech collaborations. The company's strategic shift towards diversifying its portfolio with significant investments in other clinical-stage biotech companies like Alpha Tau Medical (oncology) and real estate projects reflects a broader trend among some biotech firms to manage capital and seek alternative revenue streams or asset appreciation beyond core R&D, especially after setbacks in late-stage clinical trials. The investment in Alpha Tau, a company with encouraging clinical progress in alpha-radiation cancer therapy, positions Oramed to potentially benefit from advancements in a different therapeutic area.

Comparison to Industry Standards

• The shift from core R&D to significant financial and real estate investments is unusual for a clinical-stage pharmaceutical company, which typically focuses capital on advancing its pipeline. This strategy might be compared to a holding company or a venture capital model rather than a traditional biotech.
• The delay of a Phase 3 clinical trial due to geopolitical trade tensions (U.S.-China) is a specific external factor, not a direct comparison to industry R&D efficiency or success rates.
• The investment in Alpha Tau Medical Ltd. (16.65% stake for $36.9 million) and the right to nominate two directors suggests a strategic partnership or significant minority investment, which is common in biotech for collaboration or diversification. Alpha Tau's focus on alpha-radiation cancer therapy (Alpha DaRT) is a niche but promising area within oncology, with "encouraging clinical progress" and FDA approvals for upcoming U.S. trials, suggesting it aligns with high-potential, innovative segments of the industry.
• The substantial real estate investments ($30 million authorized, $26.92 million in loans) are a departure from typical biotech capital allocation, which usually prioritizes R&D, M&A, or returning capital to shareholders. This could be seen as a move to generate stable income or asset appreciation outside the volatile biotech market, but it also introduces new market and execution risks not typically associated with pharmaceutical companies.
• The stock buyback program extension is a common practice for companies seeking to enhance shareholder value, but its effectiveness depends on the underlying business performance and market valuation.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting agreement with KNRY Ltd., an Israeli company owned by the Chief Scientific Officer, for services.
• Employment agreement with the Chief Scientific Officer through the Subsidiary.
• Consulting agreement with Shnida Ltd., owned by the President and Chief Executive Officer, for services.
• Employment agreement with the President and Chief Executive Officer through the Subsidiary.
• Investment in Alpha Tau Medical Ltd., where Oramed has significant influence and the right to nominate two directors, making Alpha Tau a related party.
• Service Agreement with Alpha Tau for investor relations and public relations services.

Stakeholder Impact

• Shareholders: Potential for value appreciation from new investments (Alpha Tau, real estate) and the stock buyback program. However, the delay in the core oral insulin program and significant cash outflow for investments could raise concerns about long-term R&D focus and capital allocation. The Scilex warrant repurchase could provide a cash inflow.
• Employees: Continued R&D activities and preparations for a new Phase 3 trial suggest ongoing employment in R&D. Stock-based compensation plans are in place.
• Customers (future): Delay in oral insulin development means a longer wait for potential new treatments.
• Partners (HTIT): The JV is on hold due to external factors, impacting the partnership's progress.
• Creditors (Scilex): Repayments on Tranche B Note received, and an option agreement for warrant repurchase is in place, potentially extending Tranche A Note maturity.
• Regulatory Authorities: Ongoing compliance with SEC filing requirements. Nasdaq Listing Rule 5635(d) impacts warrant exercise.

Next Steps

• Evaluate whether a modified structure with HTIT is feasible under current U.S.-China trade conditions.
• Explore alternative partners and pathways to advance the oral insulin program independently.
• Initiate a Phase 3 clinical trial (ORA-D-013-3) for oral insulin, either directly or through OraTech, once clarity is achieved on the JV.
• Scilex to potentially repurchase 3,130,000 Subsequent Penny Warrants for $13,000,000 on or before September 30, 2025.
• Scilex to potentially repurchase 3,370,000 Subsequent Penny Warrants for $14,000,000 on or before December 31, 2025.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Continue to monitor and manage real estate and other financial investments for long-term value appreciation and income streams.
• RoyaltyVest continues to hold 3,000,000 warrants in BioXcel.

Key Dates

Recommendation

The company is undergoing a significant strategic pivot, moving from a primary focus on a single drug development program (oral insulin) to a diversified investment portfolio including real estate and other biotech ventures. While the Q2 net income was strong due to investment revaluations, the core oral insulin JV is delayed indefinitely due to geopolitical issues, which is a major setback. The substantial cash outflow for new investments and the decline in overall H1 net income raise questions about the long-term capital allocation strategy and the company's ability to generate sustainable returns from these diverse assets. The Scilex warrant repurchase option offers a potential cash infusion, but its completion is contingent. Given the uncertainty surrounding the core R&D pipeline and the risks associated with the new investment strategy, a 'hold' recommendation is appropriate. Investors should monitor the progress of the HTIT JV resolution, the performance of the new investments, and the company's ability to manage its cash resources effectively.

Keywords

Oral insulin, Pharmaceuticals, Biotechnology, SEC filing, 10-Q, Clinical trials, Drug development, Investments, Real estate, Scilex, Alpha Tau Medical, RoyaltyVest, HTIT, Joint venture, Warrants, Stock buyback, Financial results, Risk management, Corporate governance